ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Strategies for T Therapy in Men with Metastatic Prostate Cancer in Clinical Practice
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 189163" data-attributes="member: 13851"><p><strong>FIG. 2. <span style="color: rgb(184, 49, 47)">PSA response to various treatment strategies involving testosterone injections in a 65-year-old man at a presentation in December 2014 with biochemical recurrence after high-intensity focused ultrasound, external beam radiation, and sipuleucel-T.</span> Initial PSA was 2.9 ng/mL. Bone metastases were first identified in April 2016. Bone marrow replacement with prostate cancer noted in October 2019. <span style="color: rgb(184, 49, 47)">(A) </span>Continuous weekly injections of T cypionate 80–120 mg intramuscularly. <span style="color: rgb(184, 49, 47)">(B)</span> Combination treatment with enzalutamide and testosterone injections. Enzalutamide was taken at 40–160 mg po daily. Testosterone cypionate was administered weekly at 120–200 mg intramuscularly. Arrow indicates the beginning of combination treatment. Enzalutamide holidays and reduced doses began in October 2015, accompanied by rising PSA.<span style="color: rgb(184, 49, 47)"> (C) </span>Enzalutamide with infrequent testosterone treatments. Enzalutamide 160 mg taken daily with occasional injections of testosterone cypionate, short-acting testosterone propionate, and nasal testosterone gel. Blood tests took 2 weeks or longer after injections. <span style="color: rgb(184, 49, 47)">(D)</span> BAT. Eleven monthly injections of testosterone cypionate 400 mg intramuscularly <span style="color: rgb(184, 49, 47)">(arrows)</span> during treatment with leuprolide. Enzalutamide 160 mg added for the final 10–14 days of each cycle beginning in May 2017, as indicated. Enzalutamide discontinued after the completion of the BAT cycle in October 2017, associated with rising in PSA from 12 to 59 ng/mL. <span style="color: rgb(44, 130, 201)">BAT,</span> bipolar androgen therapy. </strong></p><p>[ATTACH=full]11167[/ATTACH]</p><p>[ATTACH=full]11168[/ATTACH]</p><p>[ATTACH=full]11169[/ATTACH]</p><p>[ATTACH=full]11170[/ATTACH]</p></blockquote><p></p>
[QUOTE="madman, post: 189163, member: 13851"] [B]FIG. 2. [COLOR=rgb(184, 49, 47)]PSA response to various treatment strategies involving testosterone injections in a 65-year-old man at a presentation in December 2014 with biochemical recurrence after high-intensity focused ultrasound, external beam radiation, and sipuleucel-T.[/COLOR] Initial PSA was 2.9 ng/mL. Bone metastases were first identified in April 2016. Bone marrow replacement with prostate cancer noted in October 2019. [COLOR=rgb(184, 49, 47)](A) [/COLOR]Continuous weekly injections of T cypionate 80–120 mg intramuscularly. [COLOR=rgb(184, 49, 47)](B)[/COLOR] Combination treatment with enzalutamide and testosterone injections. Enzalutamide was taken at 40–160 mg po daily. Testosterone cypionate was administered weekly at 120–200 mg intramuscularly. Arrow indicates the beginning of combination treatment. Enzalutamide holidays and reduced doses began in October 2015, accompanied by rising PSA.[COLOR=rgb(184, 49, 47)] (C) [/COLOR]Enzalutamide with infrequent testosterone treatments. Enzalutamide 160 mg taken daily with occasional injections of testosterone cypionate, short-acting testosterone propionate, and nasal testosterone gel. Blood tests took 2 weeks or longer after injections. [COLOR=rgb(184, 49, 47)](D)[/COLOR] BAT. Eleven monthly injections of testosterone cypionate 400 mg intramuscularly [COLOR=rgb(184, 49, 47)](arrows)[/COLOR] during treatment with leuprolide. Enzalutamide 160 mg added for the final 10–14 days of each cycle beginning in May 2017, as indicated. Enzalutamide discontinued after the completion of the BAT cycle in October 2017, associated with rising in PSA from 12 to 59 ng/mL. [COLOR=rgb(44, 130, 201)]BAT,[/COLOR] bipolar androgen therapy. [/B] [ATTACH type="full" alt="Screenshot (2231).png"]11167[/ATTACH] [ATTACH type="full" alt="Screenshot (2232).png"]11168[/ATTACH] [ATTACH type="full"]11169[/ATTACH] [ATTACH type="full"]11170[/ATTACH] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Strategies for T Therapy in Men with Metastatic Prostate Cancer in Clinical Practice
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top